Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Civacir® (Civacir) - Prophylaxis hepatitis C reinfection
Tregalizumab (BT-061) - Plaque psoriasis
Tregalizumab (BT-061) - Rheumatoid arthritis
IgM Concentrate (BT-086) - Severe community acquired pneumonia
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine (BT-062) - Solid tumors
(BT-063) - Systemic lupus erythematosus
Fibrinogen (BT-524) - Congenital and acquired fibrinogen deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Biotest and CEVEC Pharmaceuticals enter into a License ...

01.07.2015, News

Biotest and CEVEC Pharmaceuticals enter into a License Agreement regarding a cell line system for the production of tailor-made proteins - The agreement relates to CEVEC's proprietary ... [More]

Biotest's IgM Concentrate shows encouraging results in ...

30.06.2015, News

Biotest's IgM Concentrate shows encouraging results in life-threatening pneumonia - Phase II trial with IgM Concentrate completed in patients with severe community acquired ... [More]

DGAP-NVR: Biotest AG: Release according to Article 26a ...

30.06.2015, NVR

Biotest AG hereby announces that at the end of the month June 2015 the number of Voting Rights amounts to a total of 19785726 Voting Rights. It is planned that the technical execution will take ... [More]

Biotest regains rights to Tregalizumab (BT-061)

24.06.2015, News

Biotest regains rights to Tregalizumab (BT-061) - AbbVie exercised its rights to opt-out of the worldwide license, development and commercialisation agreement Dreieich, ... [More]

Biotest AG and Affibody AB enter into a Research Licens...

01.06.2015, News

Biotest AG and Affibody AB enter into a Research License and Option Agreement regarding the Albumod(TM) technology platform - Affibody's Albumod(TM) technology is designed to prolong the ... [More]

Annual general meeting approves increase of dividend an...

07.05.2015, News

Biotest AG: Annual general meeting approves increase of dividend and a share split - Dividend payment of EUR 0.60 per ordinary share and EUR 0.66 per preference share - Share split with ... [More]

Biotest increases revenues by 16,6%

07.05.2015, News

Biotest increases revenues by 16,6% - Higher Sales in the US - Capacity expansion at headquarter Dreieich in schedule Dreieich, 7 May 2015. The Biotest Group again succeeded to increase ... [More]

Biotest Phase IIb study of Tregalizumab (BT-061) in mo...

24.04.2015, News

Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million - No safety ... [More]

Biotest Phase IIb study of Tregalizumab (BT-061) in mod...

24.04.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - ... [More]

Biotest presents new clinical and preclinical results o...

23.04.2015, News

Biotest presents new clinical and preclinical results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna - Preliminary clinical results suggest that Civacir(R) reduces the ... [More]

Biotest proves effective protection from Hepatitis B vi...

23.04.2015, News

Biotest proves effective protection from Hepatitis B virus reinfection after liver transplantation in "ZEUS" study with subcutaneous hepatitis B immunoglobulin Zutectra(R) - The ... [More]

Biotest announces the opening of a plasma collection fa...

13.04.2015, News

Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US - Total number of plasma ... [More]

Biotest increases sales by 16.2%

24.03.2015, News

Biotest increases sales by 16.2% - Earnings before interest and tax (EBIT) at EUR 53.4 million - Expansion project "Biotest Next level" in timeline and budget - Share split with the ... [More]

Biotest AG: Biotest proposes capital increase from capi...

17.03.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting - Proposed capital ... [More]

DGAP-AFR: Biotest AG: Announcement according to Article...

10.03.2015, AFR

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 24, 2015 Date of disclosure / English: ... [More]

Release according to Article 26, Section 1 of the WpHG ...

23.02.2015, PVR

On February 20, 2015, Deka Investment GmbH, Frankfurt am Main, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, ... [More]

Biotest increases revenues significantly by 16.2%

13.02.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest increases revenues significantly by 16.2% Dreieich, 13. February 2015. According to preliminary and unaudited figures, ... [More]

Biotest AG:

09.02.2015, News

Biotest opens another plasma collection center in the US - Biotest continues strengthening global plasma collection with a second plasma collection center in Jacksonville, North Caroline, ... [More]

Publication according to § 26 paragraph. 1 WpHG with t...

02.02.2015, PVR

Universal-Investment-Gesellschaft mbH, 60486 Frankfurt, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, ... [More]

Encouraging Efficacy of Indatuximab Ravtansine (BT-062)...

09.12.2014, News

Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone - New data from combination therapy study presented at 56th ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialigue with the financial community.